Perioperative analgesia of intercostal nerve block versus thoracic paravertebral block in patients undergoing thoracoscopic surgery under non-tracheal intubation general anesthesia

Perioperative analgesia of intercostal nerve block versus thoracic paravertebral block in patients undergoing thoracoscopic surgery under non-tracheal intubation general anesthesia: a randomized, three-blind, non-inferiority study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052475

Enrollment

Unknown

Registered

2021-10-28

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative analgesia

Interventions

Ultrasound-guided intercostal nerve block group:Ultrasound-guided intercostal nerve block

Ultrasound-guided thoracic paravertebral block group:Ultrasound-guided thoracic paravertebral block

Eligibility

Sex/Gender

All

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: Patients undergoing thoracoscopic surgery under non-tracheal intubation general anesthesia, ASA grade I-II, no gender limitation, aged >=18 years old.

Exclusion criteria

Exclusion criteria: 1. Difficult airway (Mallampati grade >= grade III, mouth opening 30 kg/m2); 4. Coagulation disorders; 5. Airway hyperresponsiveness or excessive secretions [recent (within 2 weeks) upper respiratory tract infection or asthma attack]; 6. Higher risk of gastric contents reflux (gastroesophageal reflux disease, achalasia, etc.); 7. Nervous system disease, the patient cannot cooperate with nerve block; 8. Severe pleural adhesion or ipsilateral pneumonectomy, which affects the operation process (operation time >= 180 minutes); 9. Preoperative blood gas analysis showed hypoxemia (PaO250mmHg); 10. Various hereditary central hypoventilation syndromes; 11. Diseases that may contaminate the unaffected lung require lung isolation technology.

Design outcomes

Primary

Measure	Time frame
VAS score under coughing condition;	—

Secondary

Measure	Time frame
mean arterial pressure;heart rate;oxygen saturation;anesthesia effect score;operation field exposure score;Intraoperative amount of opioids (sufentanil, remifentanil);Blood cortisol, catecholamine, angiotensin;VAS score at rest;VAS score at rest;Effective pressing times of analgesic pump;Nausea and vomiting occurred within 48 hours after operation;length of stay;hospitalization expenses;VAS score in cough state;PGE2, ß-EP and SP;IL-6 ? IL-10 ? TNF-a;CD3+, CD4+ and CD4+/CD8+;	—

Measure

Time frame

mean arterial pressure;heart rate;oxygen saturation;anesthesia effect score;operation field exposure score;Intraoperative amount of opioids (sufentanil, remifentanil);Blood cortisol, catecholamine, angiotensin;VAS score at rest;VAS score at rest;Effective pressing times of analgesic pump;Nausea and vomiting occurred within 48 hours after operation;length of stay;hospitalization expenses;VAS score in cough state;PGE2, ß-EP and SP;IL-6 ? IL-10 ? TNF-a;CD3+, CD4+ and CD4+/CD8+;

—

Countries

China

Contacts

Public ContactZhu Rui

Huadong Hospital, Fudan university

shirley212zhr@163.com+86 15900669851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026